Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

869
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
869
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diseases of the vitreoretinal interface : What role does the vitreous body play?]

Die Ophthalmologie·2026
Same author

[Uveal effusion syndrome due to immune-mediated reaction to pembrolizumab].

Die Ophthalmologie·2025
Same author

[Predictive parameters for anatomical surgical success in full-thickness macular holes : A retrospective evaluation of 391 eyes].

Die Ophthalmologie·2024
Same author

B-scan measurements of intraocular tumor heights intraoperatively, before and after radioactive plaque application: A comparative prospective study.

Journal francais d'ophtalmologie·2023
Same author

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting.

International ophthalmology·2022
Same author

[What to do when the patient sees nothing?]

Die Ophthalmologie·2021

Related Experiment Video

Updated: Dec 14, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.2K

[Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].

F Schaub1, A M Abdullatif2, S Fauser3,4

  • 1Zentrum für Augenheilkunde, Universitätsklinikum Köln, Kerpener Str. 62, 50924, Köln, Deutschland. friederike.schaub@uk-koeln.de.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|July 16, 2020
PubMed
Summary

Pharmacological treatments for proliferative vitreoretinopathy (PVR) show promise for prevention but are not yet established for treatment. Current research focuses on anti-inflammatory and antiproliferative strategies to manage this surgical complication.

Keywords:
5‑FluorouracilDecorinPeriretinal proliferationRetinal detachmentSteroids

More Related Videos

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

8.1K
Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.4K

Related Experiment Videos

Last Updated: Dec 14, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.2K
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

8.1K
Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.4K

Area of Science:

  • Ophthalmology
  • Retinal Surgery
  • Pharmacology

Background:

  • Proliferative vitreoretinopathy (PVR) is a significant complication after vitreoretinal surgery.
  • Current standard treatment relies on surgical interventions.
  • Pharmacological strategies are being investigated to prevent and treat PVR.

Purpose of the Study:

  • To review pharmacological approaches for PVR prevention and treatment.
  • To discuss the efficacy of various anti-inflammatory and antiproliferative agents.
  • To explore novel preclinical and experimental strategies for PVR management.

Main Methods:

  • Literature review of relevant studies and clinical data.
  • Discussion of pharmacological agents targeting different phases of the PVR cascade.
  • Analysis of clinical trial outcomes for PVR prophylaxis and treatment.

Main Results:

  • Systemic prednisone showed mixed results; intravitreal triamcinolone offered no additional benefit.
  • Oral isotretinoin may reduce PVR formation post-retinal reattachment but not in established PVR.
  • Combined 5-fluorouracil and low molecular weight heparin showed positive prophylactic effects in some studies; novel approaches target growth factors, integrins, and apoptosis.

Conclusions:

  • Clinical studies primarily focus on anti-inflammatory and antiproliferative methods.
  • No pharmacological agent is currently established for PVR treatment.
  • Promising pharmacological approaches exist for PVR prophylaxis.